1. A method of treating, preventing or slowing the progression of a disease characterized by an increase and / or remodeling of atria in humans, comprising administering a therapeutically effective amount of a prodrug of an NEP inhibitor, which is N- (3-carboxy-1-oxopropyl ethyl ester) - (4S) p-phenylphenylmethyl) -4-amino (2R) methylbutanoic acid or a pharmaceutically acceptable salt thereof； or an NEP inhibitor of N- (3-carboxy-1-oxopropyl) - (4S) -p-phenylphenylmethyl) -4-amino (2R) methylbutanoic acid or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment where the disease is heart failure with a preserved ejection fraction (SN-SPS), where treatment, preventing or slowing the progression is characterized by a decrease in the volume of the left atrium, index of the volume of the left atrium (IOLP) and / or size of the left atrium. 2. A method according to claim 1, intended for the treatment or prevention of atrial fibrillation or for preventing or delaying the first manifestation of atrial fibrillation. The method according to claim 1 or 2, intended for the treatment of patients who do not have a history of atrial fibrillation. A method according to claim 1, intended for use in order to reduce the level of NT-proBNP in plasma. The method of claim 1, wherein administering a prodrug of a NEP inhibitor or an NEP inhibitor results in a steady decrease in plasma NT-proBNP concentration. The method according to claim 1, intended to improve, stabilize or slow down the deterioration according to the NYHA classification of the condition of patients suffering from heart failure. The method of claim 1, wherein the NEP inhibitor or prodrug of the NEP inhibitor is co-administered simultaneously, or1. Способ лечения, предотвращения или замедления прогрессирования заболевания, характеризующегося увеличением и/или ремоделированием предсердия, у человека,включающий введение терапевтически эффективного количества пролекарства ингибитора NEP, представ
